The partnership with Salu Inc. will provide Biogen with a direct business channel to reach top-prescribing neurologists and their patients and provide them with educational information and programmes. The agreement offers Biogen a set of services, including the creation of a Partner Resource Center on NeuroHub which provides physicians with new study information, drug updates, research information, on-line continuing medical education (CME) courses, patient education materials, and more.
"Biogen's leadership in the multiple sclerosis therapeutic area is a great fit with Salu because more than half of United States office-based neurologists are enrolled in NeuroHub", stated Jim Steeb, President and CEO of Salu. "With this agreement, Biogen can integrate NeuroHub's flexible and customisable tools and services into its overall physician communication initiatives", Mr. Steeb added.
The agreement also will provide Biogen with broader exposure for its current Internet initiatives, including its MS ActiveSource Web site, that offer MS patients and their care partners support and information to help them better manage the disease. Information about MS research and educational events, interactive learning tools, disease and therapy information, and community support can be found on the MS ActiveSource Web site. Through the agreement with Salu, MS patients will be able to access Biogen's MS ActiveSource Web site directly from their doctor's Web site along with other important disease and therapy information.
"We believe the Internet is playing an increasingly important role in patient education, and through our relationship with Salu we are pleased to make these communications tools available to neurologists and people with MS", stated Rob Perez, Vice President, CNS Business Unit of Biogen. "We value Salu's dedication and focus on specialists, in this case neurologists, because effective relationships with these physicians and their patients are of tremendous importance to us", added Mr. Perez.
Salu provides a range of speciality-specific products and services to physician-specialists, including the development of individualised Web sites to help its members deliver quality care, operate their practices more efficiently and increase revenue. Salu field representatives visit with specialists and provide them, from one integrated source, easy access to 500 proprietary tools and business consultation resources including a handheld prescription writer and a full range of products and services offered through business and pharmaceutical partners, such as Biogen. In addition, Salu's Patient Center, a secure site for physician-patient communication, combines health education, medical reference materials and secure messaging.
Biogen Inc. is a biopharmaceutical company principally engaged in discovering and developing drugs for human health care through genetic engineering. Biogen's research and development activities are focused on novel products to treat inflammatory and auto-immune diseases, neurological diseases, cancer, fibrosis, and congestive heart failure. The company maintains active clinical research programmes in protein therapeutics, small molecules, genomics, and gene therapy.
Salu has partnerships with several leading pharmaceutical companies including AstraZeneca, Elan Pharmaceuticals and Organon. Salu is also in discussions with other pharmaceutical companies focusing on neurology, as well as companies with products in various speciality categories including dermatology, gastro- enterology, and reproductive medicine. More news on the company is available in the VMW September 2001 article Salu launches HIPAA Resource Center and signs partnership with AmeriPath's Dermpath Diagnostics Division.